CAS NO: | 885220-61-1 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Verucerfont is acorticotropin-releasing factor receptor 1(CRF1) antagonist withIC50s of ~6.1, >1000 and >1000 nM for CRF1, CRF2, and CRF-BP, respectively. | ||||||||||||||||
IC50& Target | IC50: 6.1 nM (CRF1), >1000 nM (CRF2), >1000 nM (CRF-BP)[1] | ||||||||||||||||
体内研究 (In Vivo) | Post hocanalysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316 311, and pexacerfont (P<0.001 for all comparisons collapse across time-points); the latter three treatments in turn do not differ from each other. A differential effect of treatments over time is also shown by a significant treatment×time interaction (F[20,140]=6.4, P<0.001). Accordingly, detailedPost hocanalysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6 h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline)[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 406.48 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C22H26N6O2 | ||||||||||||||||
CAS 号 | 885220-61-1 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 83.33 mg/mL(205.00 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |